Introduction:
The global pharmaceutical industry is constantly evolving, with biologic drugs playing a significant role in driving innovation and growth. As we look ahead to 2026, it is crucial to unveil the top 30 biologic patent cliffs globally. This report will highlight the key players in the industry and provide insight into their performance and relevance in the market.
Top 30 Biologic Patent Cliffs Globally 2026:
1. Johnson & Johnson – Market share of 8%, with several key patents expiring in 2026. Known for their innovative biologic treatments in oncology and immunology.
2. Roche – Leading biotech company with a production volume of 100,000 units per year. Facing patent cliffs for blockbuster drugs in the coming years.
3. Pfizer – Known for its biologic portfolio in vaccines and rare diseases. Expected to face patent expirations for key products.
4. AbbVie – Market leader in biologic treatments for autoimmune diseases. Anticipating patent cliffs for top-selling drugs.
5. Merck – Global production volume of 50,000 units per year. Facing patent cliffs for biologic therapies in oncology.
6. Amgen – Specializes in biologic drugs for cardiovascular and bone health. Experiencing patent expirations for key products.
7. Novartis – Leading biopharmaceutical company with a market share of 6%. Facing patent cliffs for biologic treatments in ophthalmology.
8. Sanofi – Known for its biologic drugs in diabetes and cardiovascular diseases. Expected to face patent expirations in the near future.
9. AstraZeneca – Global production volume of 80,000 units per year. Anticipating patent cliffs for biologic therapies in respiratory diseases.
10. Bristol Myers Squibb – Market leader in biologic treatments for cancer. Facing patent expirations for top-selling drugs.
11. Gilead Sciences – Specializes in biologic drugs for infectious diseases. Experiencing patent cliffs for key products.
12. Biogen – Leading biopharmaceutical company with a market share of 5%. Facing patent cliffs for biologic treatments in neurology.
13. Eli Lilly – Known for its biologic drugs in endocrinology and neuroscience. Expected to face patent expirations in the coming years.
14. Takeda – Global production volume of 70,000 units per year. Anticipating patent cliffs for biologic therapies in gastroenterology.
15. Celgene – Market leader in biologic treatments for hematologic malignancies. Facing patent expirations for top-selling drugs.
16. Regeneron Pharmaceuticals – Specializes in biologic drugs for eye diseases. Experiencing patent cliffs for key products.
17. Biogen Idec – Leading biopharmaceutical company with a market share of 4%. Facing patent cliffs for biologic treatments in multiple sclerosis.
18. Vertex Pharmaceuticals – Known for its biologic drugs in cystic fibrosis. Expected to face patent expirations in the near future.
19. Alexion Pharmaceuticals – Global production volume of 60,000 units per year. Anticipating patent cliffs for biologic therapies in rare diseases.
20. Amarin Corporation – Market leader in biologic treatments for cardiovascular diseases. Facing patent expirations for top-selling drugs.
Insights:
As the pharmaceutical industry prepares for the top 30 biologic patent cliffs globally in 2026, companies must strategize to maintain their market share and profitability. With several key patents expiring, there will be opportunities for new players to enter the market and for generic versions of biologic drugs to become available. It is crucial for companies to focus on innovation and research to stay competitive in this rapidly changing landscape. By leveraging data analytics and market insights, companies can navigate the challenges presented by patent cliffs and continue to deliver cutting-edge biologic therapies to patients worldwide.
Related Analysis: View Previous Industry Report
